-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Insider Selling: Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Insider Sells 3,126 Shares of Stock
Insider Selling: Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Insider Sells 3,126 Shares of Stock
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Rating) insider Stephen F. Betz sold 3,126 shares of the stock in a transaction dated Monday, October 3rd. The shares were sold at an average price of $19.64, for a total value of $61,394.64. Following the completion of the sale, the insider now owns 97,472 shares of the company's stock, valued at $1,914,350.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Crinetics Pharmaceuticals Price Performance
Crinetics Pharmaceuticals stock traded down $0.61 during midday trading on Wednesday, reaching $18.44. The company's stock had a trading volume of 199,486 shares, compared to its average volume of 285,811. The stock's 50-day simple moving average is $20.33 and its 200-day simple moving average is $20.11. Crinetics Pharmaceuticals, Inc. has a 52-week low of $15.91 and a 52-week high of $28.95. The stock has a market capitalization of $991.21 million, a P/E ratio of -6.24 and a beta of 1.10.
Get Crinetics Pharmaceuticals alerts:Institutional Investors Weigh In On Crinetics Pharmaceuticals
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Driehaus Capital Management LLC raised its stake in Crinetics Pharmaceuticals by 10.7% in the second quarter. Driehaus Capital Management LLC now owns 5,474,459 shares of the company's stock valued at $102,099,000 after buying an additional 530,446 shares during the last quarter. BlackRock Inc. increased its holdings in shares of Crinetics Pharmaceuticals by 0.6% in the first quarter. BlackRock Inc. now owns 3,296,780 shares of the company's stock valued at $72,365,000 after purchasing an additional 20,610 shares during the period. Bain Capital Life Sciences Investors LLC increased its holdings in shares of Crinetics Pharmaceuticals by 13.6% in the second quarter. Bain Capital Life Sciences Investors LLC now owns 2,305,558 shares of the company's stock valued at $42,999,000 after purchasing an additional 275,857 shares during the period. State Street Corp increased its holdings in shares of Crinetics Pharmaceuticals by 3.5% in the second quarter. State Street Corp now owns 1,760,845 shares of the company's stock valued at $32,840,000 after purchasing an additional 60,166 shares during the period. Finally, Frazier Life Sciences Management L.P. acquired a new position in shares of Crinetics Pharmaceuticals in the first quarter valued at about $31,055,000. 94.42% of the stock is currently owned by hedge funds and other institutional investors.
Crinetics Pharmaceuticals Company Profile
(Get Rating)Crinetics Pharmaceuticals, Inc, a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs).
Featured Articles
- Get a free copy of the StockNews.com research report on Crinetics Pharmaceuticals (CRNX)
- Hot Potato: Lamb Weston Stock Confirms a Top
- Too Soon: 3 Reasons to Wait on DocuSign Stock
- Rite-Aid Sings a Familiar Tune That Investors Don't Want to Hear
- Don't Give Up on These Q3 Losers
- The Anatomy of a Great Pension Plan
Receive News & Ratings for Crinetics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crinetics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Rating) insider Stephen F. Betz sold 3,126 shares of the stock in a transaction dated Monday, October 3rd. The shares were sold at an average price of $19.64, for a total value of $61,394.64. Following the completion of the sale, the insider now owns 97,472 shares of the company's stock, valued at $1,914,350.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Crinetics製藥公司(納斯達克代碼:CRNX-GET評級)內部人士斯蒂芬·F·貝茨在一筆日期為10月3日星期一的交易中出售了3,126股該股。這些股票的平均價格為19.64美元,總價值為61,394.64美元。出售完成後,這位內部人士現在擁有該公司97,472股股票,價值1,914,350.08美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,該文件可通過此超鏈接.
Crinetics Pharmaceuticals Price Performance
Crinetics藥品價格表現
Crinetics Pharmaceuticals stock traded down $0.61 during midday trading on Wednesday, reaching $18.44. The company's stock had a trading volume of 199,486 shares, compared to its average volume of 285,811. The stock's 50-day simple moving average is $20.33 and its 200-day simple moving average is $20.11. Crinetics Pharmaceuticals, Inc. has a 52-week low of $15.91 and a 52-week high of $28.95. The stock has a market capitalization of $991.21 million, a P/E ratio of -6.24 and a beta of 1.10.
週三午盤交易中,Crinetics PharmPharmticals股價下跌0.61美元,至18.44美元。該公司股票的成交量為199,486股,而其平均成交量為285,811股。該股的50日簡單移動均線切入位為20.33美元,200日簡單移動均線切入位為20.11美元。Crinetics PharmPharmticals,Inc.的52周低點為15.91美元,52周高位為28.95美元。該股市值為9.9121億美元,市盈率為-6.24,貝塔係數為1.10。
Institutional Investors Weigh In On Crinetics Pharmaceuticals
機構投資者看好Crinetics製藥公司
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Driehaus Capital Management LLC raised its stake in Crinetics Pharmaceuticals by 10.7% in the second quarter. Driehaus Capital Management LLC now owns 5,474,459 shares of the company's stock valued at $102,099,000 after buying an additional 530,446 shares during the last quarter. BlackRock Inc. increased its holdings in shares of Crinetics Pharmaceuticals by 0.6% in the first quarter. BlackRock Inc. now owns 3,296,780 shares of the company's stock valued at $72,365,000 after purchasing an additional 20,610 shares during the period. Bain Capital Life Sciences Investors LLC increased its holdings in shares of Crinetics Pharmaceuticals by 13.6% in the second quarter. Bain Capital Life Sciences Investors LLC now owns 2,305,558 shares of the company's stock valued at $42,999,000 after purchasing an additional 275,857 shares during the period. State Street Corp increased its holdings in shares of Crinetics Pharmaceuticals by 3.5% in the second quarter. State Street Corp now owns 1,760,845 shares of the company's stock valued at $32,840,000 after purchasing an additional 60,166 shares during the period. Finally, Frazier Life Sciences Management L.P. acquired a new position in shares of Crinetics Pharmaceuticals in the first quarter valued at about $31,055,000. 94.42% of the stock is currently owned by hedge funds and other institutional investors.
一些對衝基金和其他機構投資者最近增持或減持了該業務的股份。Driehaus Capital Management LLC在第二季度將其在Crinetics PharmPharmticals的持股增加了10.7%。Driehaus Capital Management LLC在上個季度額外購買了530,446股後,現在擁有5,474,459股該公司股票,價值102,099,000美元。貝萊德股份有限公司在第一季度增持了Crinetics PharmPharmticals的股票0.6%。貝萊德股份有限公司在此期間增持了20,610股,目前持有該公司3,296,780股股票,價值72,365,000美元。貝恩資本生命科學投資者有限責任公司在第二季度增持了13.6%的Crinetics PharmPharmticals股票。貝恩資本生命科學投資者有限責任公司現在擁有該公司2,305,558股股票,價值42,999,000美元,在此期間又購買了275,857股。道富集團第二季度增持Crinetics PharmPharmticals股票3.5%。道富銀行目前持有1,760,845股該公司股票,價值32,840,000美元,在此期間又購買了60,166股。最後,弗雷澤生命科學管理公司在第一季度收購了Crinetics製藥公司的新股票,價值約31,055,000美元。94.42%的股票目前由對衝基金和其他機構投資者持有。
Crinetics Pharmaceuticals Company Profile
Crinetics製藥公司簡介
Crinetics Pharmaceuticals, Inc, a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs).
Crinetics製藥公司是一家臨牀階段製藥公司,專注於罕見內分泌疾病和內分泌相關腫瘤治療藥物的發現、開發和商業化。它的主要候選產品是Paltusotine,這是一種口服選擇性非肽生長抑素受體2型激動劑,已經完成了治療肢端肥大症的第三階段臨牀試驗,以及治療類癌綜合徵和無功能神經內分泌腫瘤(NETS)的第二階段臨牀試驗。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on Crinetics Pharmaceuticals (CRNX)
- Hot Potato: Lamb Weston Stock Confirms a Top
- Too Soon: 3 Reasons to Wait on DocuSign Stock
- Rite-Aid Sings a Familiar Tune That Investors Don't Want to Hear
- Don't Give Up on These Q3 Losers
- The Anatomy of a Great Pension Plan
- 免費獲取StockNews.com的Crinetics PharmPharmticals研究報告(CRNX)
- 辣土豆:韋斯頓羊肉庫存漲幅居前
- 太快:等待DocuSign股票的三個理由
- 禮儀援助唱出了投資者不願聽到的熟悉曲調
- 不要放棄這些第三季度的失敗者
- 一個偉大的養老金計劃的剖析
Receive News & Ratings for Crinetics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crinetics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
獲得《Crinetics PharmPharmticals Daily》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Crinetics製藥和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧